CO-188: Product/Procedure Not Covered Unless FDA-Recommended

What Does CO-188 Mean?

CO-188 is the standard pairing and means the payer considers the non-FDA-compliant usage to be a coverage issue under the provider's contract. The denied amount is the provider's contractual write-off unless successfully appealed. The provider cannot bill the patient for the denied amount under CO, making a strong appeal critical for cost recovery.

CARC 188 appears on your remittance when the payer denies coverage for a product, device, medication, or procedure because it was not used in accordance with FDA recommendations. This is a coverage denial tied specifically to FDA compliance — the payer is not questioning whether the patient needed treatment, but whether the specific product or procedure was used for an FDA-approved purpose.

The most common trigger is off-label usage. When a medication, device, or product is used for an indication not listed in its FDA-approved labeling, many payers will deny coverage unless the off-label use is supported by recognized medical compendia or peer-reviewed literature. The second most frequent cause is documentation failure — the product may have been used correctly, but the medical record does not explicitly document the FDA-approved indication, leaving the payer unable to verify compliance.

This code carries significant financial risk because it often applies to high-cost items — specialty drugs, implantable devices, and advanced biological products. The resolution path almost always involves an appeal rather than a simple resubmission, because you need to demonstrate either that the use was FDA-compliant or that the off-label use meets recognized compendium standards. Many payers will cover off-label uses if they are supported by sources like the National Comprehensive Cancer Network (NCCN) compendium or other recognized clinical references.

Common Causes

How to Resolve

Document that the product or procedure was used in accordance with FDA recommendations or recognized compendium standards, and submit a clinical appeal.

1. Build the clinical case Document exactly how the product or procedure was used, match it against the FDA-approved labeling, and identify any gaps between the documented use and the approved indications.
2. Submit appeal with FDA evidence File an appeal that includes the FDA product labeling, clinical documentation showing the approved indication, the patient's diagnosis, and a physician attestation of medical necessity.
3. Pursue off-label coverage if applicable If the use was off-label, submit compendium citations and peer-reviewed literature supporting the clinical efficacy of the off-label use. Reference the payer's off-label coverage policy.
4. Escalate if needed If the initial appeal is denied, request a peer-to-peer review or escalate to external review, especially for high-cost products where the financial impact is significant.

Common RARC Pairings

The RARC code tells you exactly what triggered the CO-188:

How to Prevent CO-188

• Document the specific FDA-approved indication in the medical record whenever prescribing or using a product or procedure
• Obtain pre-authorization for products or procedures where the payer requires FDA-compliance verification
• Train clinical staff on the importance of documenting FDA-compliant usage and maintain current knowledge of FDA label changes
• Implement a coding review process that matches diagnosis codes to FDA-approved indications before claim submission

General Prevention

• Verify that products and procedures are being used for FDA-approved indications before service delivery and document the FDA-compliant use in the medical record
• Obtain pre-authorization from the payer when required, specifically confirming coverage for the intended use of the product or procedure
• Train clinical staff on FDA-recommended uses of products and procedures and the importance of documenting compliant usage
• Maintain current knowledge of FDA approvals, label changes, and off-label coverage policies for each payer
• Implement a coding review process that ensures the diagnosis and procedure codes accurately reflect FDA-approved indications

Also Filed As

The same CARC 188 may appear with different Group Codes:

Related Denial Codes